Astrazeneca 31 (50UC)
LSE
Year End December 30 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Revenue | 23B | 22.47B | 22.09B | 24.38B | 26.62B | 37.42B | 44.35B | 45.81B |
Operating Income | 3.68B | 2.09B | 1.4B | 1.59B | 4.08B | -293M | 3.54B | 7.89B |
Pre Tax Income | 3.55B | 2.23B | 1.99B | 1.55B | 3.92B | -265M | 2.5B | 6.9B |
Net Income | 3.5B | 3B | 2.16B | 1.34B | 3.2B | 112M | 3.29B | 5.96B |
Preferred Dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Basic Earnings Per Share (EPS) | 2.766 | 2.37 | 1.701 | 1.017 | 2.435 | 0.072 | 2.122 | 3.842 |
EBIT | 4.87B | 3.46B | 3.27B | 2.81B | 5.14B | 216M | 3.75B | 8.18B |
EBITDA | 6.04B | 5.11B | 5.15B | 5.35B | 7.23B | 6.24B | 9.02B | 13.28B |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.